neoantigen-loaded dendritic cell vaccine (NeoDC-Vac)
Phase 2Vaccine
neoantigen-loaded dendritic cell vaccine (NeoDC-Vac) is one of 47 biologic programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
46
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
241 competitors in Esophageal Squamous Cell Carcinoma
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Camptosar
PfizerPhase 3
Keytruda
Merck & Co.Phase 3
Imfinzi
AstraZenecaPhase 3
Eloxatin
TevaPhase 3
Tecentriq
RochePhase 3
Opdivo
Bristol-Myers SquibbPhase 3
Tyvyt
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
Bayer Aspirin
BayerPhase 3
Taxotere
AAvyxa
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Vaccine[2]
- Highest Phase
- Phase 2[1]
- Company
- SSichuan University